Introduction
============

*Familial Mediterranean Fever* (*FMF*) is an autosomal recessive disease that is prevalent among eastern Mediterranean populations, mainly non-Ashkenazi Jews, Armenians, Turks, and Arabs. Arthritis seen in FMF patients is generally acute monoarthritis which predominantly affecting the lower limbs, and it occurs during attack periods and also is a common clinical manifestation in patients with FMF alike Rheumatoid arthritis (RA). *Anti-cyclic citrullinated peptide* (*anti-CCP*) *antibodies* testing is useful in the diagnosis of Rheumatoid arthritis with high specificity. The citrulline residues are essential part of the antigenic determinants recognized by the RA antibodies.

Objectives
==========

The aim of the study was to show the presence of anti-cyclic citrullinated peptide (anti-CCP) antibodies in child individuals diagnosed with Familial Mediterranean Fever (FMF) .

Methods
=======

The study group was comprised of one hundred and twenty six patients diagnosed with FMF (female/male (n):66/60); and fifthy healthy control (female/male(n):25/25) . Clinical and laboratory assessments of the FMF patients were performed during attack-free periods. Erythrocyte sedimentation rate (ESR), serum C-reactive protein (CRP), fibrinogen and anti-CCP antibody levels were measured.

Results
=======

Anti-CCP results were negative in healthy controls and also in all FMF patients. There was not a significant difference in anti-CCP between the patient and the control groups. The patient individuals were divided into four groups according to genetic mutation analysis. The groups has been comprised as M694V/M694V(n=26), M694V/Other(n=38), Other/Other(n=46),Negative(n=16). No significant difference detected between four mutation groups and anti-CCP levels. Our study has shown moderate positive correlations between age (r~s~= 0.271; p= 0.0020), duration of illness (r~s~= 0.331; p\<0.0001), colchicinetherapy (r~s~= 0.259; p= 0.004) and anti-CCP levels. Also poor positive correlations between fibrinogen and anti ccp levels was detected (r~s~= 0.192; p= 0.0330). Anti-CCP levels has not shown significance between patients with or without arthritis(p=0.148).

Conclusion
==========

In conclusion, no published data in children establish anti-CCP values in patients with FMF compared with healthy controls. Our data show that anti-CCP antibodies are not associated with FMF. Anti-CCP does not have a priority for identifying FMF arthritis from the other inflammatory arthritis.

Disclosure of interest
======================

None declared.
